Woyach JA, Ruppert AS, Heerema NA et al (2018) Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med 379:2517–2528

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shanafelt TD, Wang XV, Kay NE et al (2019) Ibrutinib–rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med 381:432–443

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fischer K, Al-Sawaf O, Bahlo J et al (2019) Venetoclax and Obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med 380:2225–2236

Article  CAS  PubMed  Google Scholar 

Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW et al (2020) Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet 395(10232):1278–91

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gunawardana C, Austen B, Powell JE et al (2008) South Asian chronic lymphocytic leukaemia patients have more rapid disease progression in comparison to white patients. Br J Haematol 142:606–609

Article  PubMed  Google Scholar 

Agrawal N, Naithani R, Mahapatra M et al (2007) Chronic lymphocytic leukemia in India–a clinico-hematological profile. Hematology 12:229–233

Article  PubMed  Google Scholar 

Hallek M (2019) Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. Am J Hematol 94(11):1266–1287. https://doi.org/10.1002/ajh.25595

Article  PubMed  Google Scholar 

Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H et al (2018) iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 131(25):2745–2760

Article  CAS  PubMed  Google Scholar 

Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C et al (2016) First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol 17(7):928–942

Article  CAS  PubMed  Google Scholar 

Tejaswi V, Lad DP, Jindal N et al (2020) Chronic lymphocytic leukemia: real-world data from India. JCO Glob Oncol 6:866–872. https://doi.org/10.1200/GO.20.00032

Article  CAS  PubMed  Google Scholar 

Knauf WU, Lissitchkov T, Aldaoud A, Liberati AM, Loscertales J, Herbrecht R, Juliusson G, Postner G, Gercheva L, Goranov S, Becker M, Fricke HJ, Huguet F, Del Giudice I, Klein P, Merkle K, Montillo M (2012) Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial. Br J Haematol 159(1):67–77. https://doi.org/10.1111/bjh.12000

Article  CAS  PubMed  Google Scholar 

Sathyanarayanan V, Flowers CR, Iyer SP (2020) Comparison of access to novel drugs for lymphoma and chronic lymphocytic leukemia between India and the United States. JCO Glob Oncol 6:1124–1133. https://doi.org/10.1200/GO.20.00012

Article  PubMed  Google Scholar 

Sood N, Varghese A, Chakrabarty J, Chezhian S, Sopory P (2021) Acalabrutinib in management of chronic lymphocytic leukemia: an Indian perspective. eJHaem 2(3):628–634. https://doi.org/10.1002/jha2.227

Article  CAS  PubMed  PubMed Central  Google Scholar 

Agarwal MB, Bhurani D, Shah C et al (2017) Efficacy and safety of Ibrutinib in Indian patients with relapsed or refractory chronic lymphocytic Leukemia and mantle cell lymphoma: cases from a named patient program. Indian J Med Paediatr Oncol 38(4):508–515. https://doi.org/10.4103/ijmpo.ijmpo_43_17

Article  PubMed  PubMed Central  Google Scholar 

Lad DP, Malhotra P, Khadwal A, Prakash G, Jain A, Varma S (2019) Reduced Dose Ibrutinib Due to Financial Toxicity in CLL. Indian J Hematol Blood Transfus. 35(2):260–264. https://doi.org/10.1007/s12288-018-1011-4

Article  PubMed  Google Scholar